¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

Á¦ 19 ȸ ´ëÇѳú¿°/³ú¿°ÁõÇÐȸ Ãá°èÇмú´ëȸ : 2023-04-15

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 

Á¦ 19 ȸ ´ëÇѳú¿°/³ú¿°ÁõÇÐȸ Ãá°èÇмú´ëȸ : 2023-04-15
±³À°ÀÏÀÚ : 2023-04-15
±³À°Àå¼Ò : ¼­¿ï ¼­¿ï´ëÇб³º´¿ø ÀÇ»ý¸í¿¬±¸¿ø ÀÇÇבּ¸Çõ½Å¼¾ÅÍ CMI 1Ãþ ¼­¼ºÈ¯¿¬±¸È¦

±³À°ÁÖÁ¦ : Á¦ 19 ȸ ´ëÇѳú¿°/³ú¿°ÁõÇÐȸ Ãá°èÇмú´ëȸ

ÁÖÃÖ±â°ü : ´ëÇѽŰæ°úÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ´ëÇѳú¿°/³ú¿°ÁõÇÐȸ

´ã´çÀÚ : ´ëÇѳú¿°³ú¿°ÁõÇÐȸ »ç¹«±¹
¿¬¶ôó : 02-2072-0629

À̸ÞÀÏ : encephalitis.office@kens.or.kr

±³À°Á¾·ù : ½Å°æ°ú

Âü¼®¿¹»óÀοø : 80¸í
Èñ¸ÁÆòÁ¡ : 5Á¡

Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 5 ½Ã°£ 20ºÐ

¼¼ºÎ¼ö°­·á : 0¿ø  

ºñ°í


±¸ºÐ ¿ùÀÏ °­ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ

±âŸ 04-15 ¼­¿ï ¼­¿ï´ëÇб³º´¿ø ÀÇ»ý¸í¿¬±¸¿ø ÀÇÇבּ¸Çõ½Å¼¾ÅÍ CMI 1Ãþ ¼­¼ºÈ¯¿¬±¸È¦ 09:00~09:30 ÇöÀåµî·Ï ()

±³À°½Ã°£ 04-15 ¼­¿ï ¼­¿ï´ëÇб³º´¿ø ÀÇ»ý¸í¿¬±¸¿ø ÀÇÇבּ¸Çõ½Å¼¾ÅÍ CMI 1Ãþ ¼­¼ºÈ¯¿¬±¸È¦ 09:30~09:45 A 31-year-old female with Refractory Primary CNS Vasculitis: What is the next possible alternative therapy? ÀåÀ±Çõ(¼­¿ï´ëº´¿ø)

±³À°½Ã°£ 04-15 ¼­¿ï ¼­¿ï´ëÇб³º´¿ø ÀÇ»ý¸í¿¬±¸¿ø ÀÇÇבּ¸Çõ½Å¼¾ÅÍ CMI 1Ãþ ¼­¼ºÈ¯¿¬±¸È¦ 09:45~10:00 Neuronal Intranuclear Inclusion Disease in an Adult Patient: A Diagnostic Challenge ½Å¿ë¿ì(¼­¿ï´ëº´¿ø)

±³À°½Ã°£ 04-15 ¼­¿ï ¼­¿ï´ëÇб³º´¿ø ÀÇ»ý¸í¿¬±¸¿ø ÀÇÇבּ¸Çõ½Å¼¾ÅÍ CMI 1Ãþ ¼­¼ºÈ¯¿¬±¸È¦ 10:00~10:15 A 46-year old man with new-onset seizures È«»óºó(¼­¿ï´ëº´¿ø)

±³À°½Ã°£ 04-15 ¼­¿ï ¼­¿ï´ëÇб³º´¿ø ÀÇ»ý¸í¿¬±¸¿ø ÀÇÇבּ¸Çõ½Å¼¾ÅÍ CMI 1Ãþ ¼­¼ºÈ¯¿¬±¸È¦ 10:15~10:30 25-year-old woman with drug resistant epilepsy : A case of autoimmune epilepsy ÀÌÀ±°æ(µ¿¾Æ´ëº´¿ø)

ÈÞ½Ä 04-15 ¼­¿ï ¼­¿ï´ëÇб³º´¿ø ÀÇ»ý¸í¿¬±¸¿ø ÀÇÇבּ¸Çõ½Å¼¾ÅÍ CMI 1Ãþ ¼­¼ºÈ¯¿¬±¸È¦ 10:30~10:50 COFFEE BREAK ()

±³À°½Ã°£ 04-15 ¼­¿ï ¼­¿ï´ëÇб³º´¿ø ÀÇ»ý¸í¿¬±¸¿ø ÀÇÇבּ¸Çõ½Å¼¾ÅÍ CMI 1Ãþ ¼­¼ºÈ¯¿¬±¸È¦ 10:50~11:05 A case of LGI-1 antibody encephalitis with schizophrenia like symptom as an initial clinical manifestation ¼Û¿øºó(°¡Å縯°üµ¿´ë ±¹Á¦¼º¸ðº´¿ø)

±³À°½Ã°£ 04-15 ¼­¿ï ¼­¿ï´ëÇб³º´¿ø ÀÇ»ý¸í¿¬±¸¿ø ÀÇÇבּ¸Çõ½Å¼¾ÅÍ CMI 1Ãþ ¼­¼ºÈ¯¿¬±¸È¦ 11:05~11:20 Scrub typhus ±è±ÙÅÂ(°è¸í´ëµ¿»êº´¿ø)

±³À°½Ã°£ 04-15 ¼­¿ï ¼­¿ï´ëÇб³º´¿ø ÀÇ»ý¸í¿¬±¸¿ø ÀÇÇבּ¸Çõ½Å¼¾ÅÍ CMI 1Ãþ ¼­¼ºÈ¯¿¬±¸È¦ 11:20~11:35 A case of multiple cranial neuropathy after zoster ophthalmicus Ȳ¼ºÀº()

±³À°½Ã°£ 04-15 ¼­¿ï ¼­¿ï´ëÇб³º´¿ø ÀÇ»ý¸í¿¬±¸¿ø ÀÇÇבּ¸Çõ½Å¼¾ÅÍ CMI 1Ãþ ¼­¼ºÈ¯¿¬±¸È¦ 11:35~11:50 An 18-year-old male with seizure and anti-N-methyl-D-aspartate receptor antibody ±èÅÂÁØ(¾ÆÁִ뺴¿ø)

½Ä»ç 04-15 ¼­¿ï ¼­¿ï´ëÇб³º´¿ø ÀÇ»ý¸í¿¬±¸¿ø ÀÇÇבּ¸Çõ½Å¼¾ÅÍ CMI 1Ãþ ¼­¼ºÈ¯¿¬±¸È¦ 11:50~13:00 LUNCH ()

±³À°½Ã°£ 04-15 ¼­¿ï ¼­¿ï´ëÇб³º´¿ø ÀÇ»ý¸í¿¬±¸¿ø ÀÇÇבּ¸Çõ½Å¼¾ÅÍ CMI 1Ãþ ¼­¼ºÈ¯¿¬±¸È¦ 13:00~13:25 VTE treatment and Prophylaxis for Neurologic patient ³ª»óÈÆ(¼­¿ï´ëº´¿ø)

±³À°½Ã°£ 04-15 ¼­¿ï ¼­¿ï´ëÇб³º´¿ø ÀÇ»ý¸í¿¬±¸¿ø ÀÇÇבּ¸Çõ½Å¼¾ÅÍ CMI 1Ãþ ¼­¼ºÈ¯¿¬±¸È¦ 13:25~13:50 Immunotherapy and infection risk ÀÌÇÑ»ó(¼­¿ï´ëº´¿ø)

±³À°½Ã°£ 04-15 ¼­¿ï ¼­¿ï´ëÇб³º´¿ø ÀÇ»ý¸í¿¬±¸¿ø ÀÇÇבּ¸Çõ½Å¼¾ÅÍ CMI 1Ãþ ¼­¼ºÈ¯¿¬±¸È¦ 13:50~14:15 Psychiatric symptom care in neurologic ward ±è¹Î¾Æ(¼­¿ï´ëº´¿ø)

±³À°½Ã°£ 04-15 ¼­¿ï ¼­¿ï´ëÇб³º´¿ø ÀÇ»ý¸í¿¬±¸¿ø ÀÇÇבּ¸Çõ½Å¼¾ÅÍ CMI 1Ãþ ¼­¼ºÈ¯¿¬±¸È¦ 14:15~14:40 Breaking bad news and ethical decision À̼øÅÂ(¼­¿ï´ëº´¿ø)

ÈÞ½Ä 04-15 ¼­¿ï ¼­¿ï´ëÇб³º´¿ø ÀÇ»ý¸í¿¬±¸¿ø ÀÇÇבּ¸Çõ½Å¼¾ÅÍ CMI 1Ãþ ¼­¼ºÈ¯¿¬±¸È¦ 14:40~15:00 COFFEE BREAK ()

±³À°½Ã°£ 04-15 ¼­¿ï ¼­¿ï´ëÇб³º´¿ø ÀÇ»ý¸í¿¬±¸¿ø ÀÇÇבּ¸Çõ½Å¼¾ÅÍ CMI 1Ãþ ¼­¼ºÈ¯¿¬±¸È¦ 15:00~15:25 Glymphatic evaluation using MRI ÃÖ½ÂÈ«(¼­¿ï´ëº´¿ø)

±³À°½Ã°£ 04-15 ¼­¿ï ¼­¿ï´ëÇб³º´¿ø ÀÇ»ý¸í¿¬±¸¿ø ÀÇÇבּ¸Çõ½Å¼¾ÅÍ CMI 1Ãþ ¼­¼ºÈ¯¿¬±¸È¦ 15:25~15:50 Macrophage activation syndrome ¹ÚÁø±Õ(¼­¿ï´ëº´¿ø)

±³À°½Ã°£ 04-15 ¼­¿ï ¼­¿ï´ëÇб³º´¿ø ÀÇ»ý¸í¿¬±¸¿ø ÀÇÇבּ¸Çõ½Å¼¾ÅÍ CMI 1Ãþ ¼­¼ºÈ¯¿¬±¸È¦ 15:50~16:15 Seizure management in encephalitis patients ÁÖ°Ç(¼­¿ï´ëº´¿ø)

±³À°½Ã°£ 04-15 ¼­¿ï ¼­¿ï´ëÇб³º´¿ø ÀÇ»ý¸í¿¬±¸¿ø ÀÇÇבּ¸Çõ½Å¼¾ÅÍ CMI 1Ãþ ¼­¼ºÈ¯¿¬±¸È¦ 16:15~16:40 Recent Advances in Gene Therapy for Rare Diseases ¹®Àå¼·(¼­¿ï´ëº´¿ø)

 

ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" Á¦ 19 ȸ ´ëÇѳú¿°/³ú¿°ÁõÇÐȸ Ãá°èÇмú´ëȸ : 2023-04-15""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û Á¦43ȸ ´ëÇÑÀÓ»óÇǺÎÄ¡·á¿¬±¸È¸ ±³À°½ÉÆ÷Áö¾ö : 2023-04-15
´ÙÀ½±Û ±¹¸³Áß¾ÓÀÇ·á¿ø Àü¹® ±âµµ°ü¸® ½Ã¹Ä·¹ÀÌ¼Ç : 2023-04-15
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
21197 °æºÏ Çѱ¹Ãµ½Ä¾Ë·¹¸£±âÇùȸ 2024 Post Graduate Asthma School (1ÀÏÂ÷) : 2024-08-24 0 0 2024-07-02
21196 ¼­¿ï ´ëÇÑ¿Ü°ú´ë»ç¿µ¾çÇÐȸ Enhanced Recovery After Surgery(ERAS) Symposium : 2024-08-23 0 0 2024-07-02
21195 ¼­¿ï [¿Â¶óÀÎ] Áø´Ü¿ë ¹æ»ç¼± ¾ÈÀü°ü¸®Ã¥ÀÓÀÚ ¼±ÀÓ±³À° : 2024-08-22 0 0 2024-07-02
21194 ¼­¿ï Á¦22ȸ ±è¾È°úº´¿ø ½ÉÆ÷Áö¾ö - ¹é³»Àå/±¼Àý : 2024-08-18 0 0 2024-07-02
21193 ¼­¿ï °í·Á´ëÇб³ ÀÇ°ú´ëÇÐ Rhinology update symposium in 2024 : 2024-08-18 0 0 2024-07-02
21192 ¼­¿ï ÇѽŰæ¸é¿ªÇÐȸ 2024³â ÇÏ°èÇмú´ëȸ : 2024-08-17 0 1 2024-07-02
21191 ¼­¿ï ´ëÇÑÀÓ»óÃÊÀ½ÆÄÇÐȸ Á¦24ȸ Ãá°èÇмú´ëȸ : 2024-08-11 0 11 2024-07-02
21190 ¼­¿ï 2024³â ´ëÇÑÇǺΰúÇÐȸ ¼­¿ïÁöºÎȸ Ä¡·á ½ÉÆ÷Áö¾ö : 2024-08-03 0 9 2024-07-02
21189 ¼­¿ï (¿Â¶óÀÎ) ÀÇ·á±â°ü Á¾»çÀÚ ´ë»ó ¿¬¸íÀÇ·á°áÁ¤Á¦µµ ±âº»±³À° : 2024-07-30 0 8 2024-07-02
21188 ¼­¿ï (¿Â¶óÀÎ) ÀÇ·á±â°ü Á¾»çÀÚ(À§¿øȸ) ´ë»ó ¿¬¸íÀÇ·á°áÁ¤Á¦µµ ½ÉÈ­±³À° : 2024-07-30 0 10 2024-07-02
21187 ¼­¿ï °­³²¼¼ºê¶õ½ºº´¿ø ¼ºÇü¿Ü°ú °­³²Áý´ãȸ(´«Áö¹æÀ̽Ä, ºñÀý°³¹ý, Àý°³¹ý) : 2024-07-27 0 3 2024-07-02
21186 ¼­¿ï 2024³âµµ ÇϹݱâ ÀÓ»óÁø·áÁöħ ±³À° ¿öÅ©¼ó : ¡¸ÀÓ»óÁø·áÁöħÀÇ °³¹ß¡¹ ½ÇÇàÇϱâ - ¹®Çå°Ë»ö°ú Áú Æò°¡ : 2024-07-27 0 1 2024-07-02
21185 ´ë±¸ ¿µ³²»ý½Ä³»ºÐºñ ÇÐȸ Çмú½ÉÆ÷Áö¾ö : 2024-07-27 0 3 2024-07-02
21184 ÀüºÏ ¿ø±¤´ëÇб³º´¿ø Á¦12ȸ ¿ø±¤ ½ÉÀüµµ ½ÉÆ÷Áö¿ò : 2024-07-27 0 12 2024-07-02
21183 Ãæ³² 2024³â Á¦14ȸ ´ëÇÑÀü¸³¼±ÇÐȸ-´ëÇѹ财Àå¾Ö¿ä½Ç±ÝÇÐȸ °øµ¿½ÉÆ÷Áö¾ö : 2024-07-27 0 3 2024-07-02
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷